Hyris developed a rapid T-Cell test, which leverages the power of the Hyris SystemTM to track patients' immunity levels to SARS-CoV-2 for research and global clinical use. The new test has been brought to market after having inked an exclusive licensing agreement with Singapore Duke-NUS Medical School.